Shares of Tilray Inc (NASDAQ:TLRY) have been assigned an average recommendation of “Hold” from the fifteen brokerages that are currently covering the company, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, ten have given a hold recommendation and three have assigned a buy recommendation to the company. The average 1 year target price among brokerages that have covered the stock in the last year is $84.52.

Several analysts have issued reports on the stock. Compass Point assumed coverage on shares of Tilray in a report on Monday, June 10th. They issued a “neutral” rating and a $41.00 price target on the stock. Stifel Nicolaus assumed coverage on shares of Tilray in a report on Wednesday, June 5th. They issued a “hold” rating and a $37.00 price target on the stock. Oppenheimer assumed coverage on shares of Tilray in a report on Tuesday, June 4th. They issued a “market perform” rating on the stock. Zacks Investment Research raised shares of Tilray from a “sell” rating to a “hold” rating in a report on Tuesday, May 21st. Finally, Piper Jaffray Companies reduced their price target on shares of Tilray from $84.00 to $72.00 and set an “overweight” rating on the stock in a report on Wednesday, May 15th.

Shares of NASDAQ TLRY traded down $1.69 on Friday, hitting $39.01. The company’s stock had a trading volume of 1,368,107 shares, compared to its average volume of 1,637,399. Tilray has a 12-month low of $20.10 and a 12-month high of $300.00. The company has a market capitalization of $3.96 billion and a PE ratio of -47.57. The company has a debt-to-equity ratio of 1.13, a current ratio of 2.35 and a quick ratio of 2.06.

Tilray (NASDAQ:TLRY) last announced its quarterly earnings results on Tuesday, May 14th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.25) by ($0.02). Tilray had a negative net margin of 159.09% and a negative return on equity of 43.71%. The business had revenue of $23.00 million during the quarter, compared to analysts’ expectations of $20.50 million. The firm’s revenue was up 194.9% compared to the same quarter last year. On average, analysts forecast that Tilray will post -0.89 EPS for the current fiscal year.

In other news, CRO Edward Wood Pastorius, Jr. sold 46,557 shares of the business’s stock in a transaction that occurred on Tuesday, April 2nd. The shares were sold at an average price of $63.38, for a total value of $2,950,782.66. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Brendan Kennedy sold 106,109 shares of the business’s stock in a transaction that occurred on Tuesday, April 2nd. The shares were sold at an average price of $63.44, for a total transaction of $6,731,554.96. The disclosure for this sale can be found here. In the last three months, insiders sold 166,109 shares of company stock valued at $10,409,698. Company insiders own 3.40% of the company’s stock.

Several large investors have recently bought and sold shares of the company. Zevenbergen Capital Investments LLC raised its position in shares of Tilray by 37.1% in the first quarter. Zevenbergen Capital Investments LLC now owns 730,280 shares of the company’s stock valued at $47,848,000 after buying an additional 197,540 shares during the last quarter. Morgan Stanley raised its position in shares of Tilray by 39.6% in the first quarter. Morgan Stanley now owns 229,152 shares of the company’s stock valued at $15,014,000 after buying an additional 65,032 shares during the last quarter. Essex Investment Management Co. LLC acquired a new position in shares of Tilray in the first quarter valued at approximately $5,954,000. Hellman Jordan Management Co. Inc. MA acquired a new position in shares of Tilray in the first quarter valued at approximately $3,276,000. Finally, Stevens Capital Management LP acquired a new position in shares of Tilray in the first quarter valued at approximately $2,106,000. 2.04% of the stock is owned by institutional investors and hedge funds.

Tilray Company Profile

Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc is headquartered in Nanaimo, Canada.

Featured Story: Cash Asset Ratio

Analyst Recommendations for Tilray (NASDAQ:TLRY)

Receive News & Ratings for Tilray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tilray and related companies with MarketBeat.com's FREE daily email newsletter.